All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Myeloproliferative neoplasms (MPN) are associated with a high prevalence of thrombosis at diagnosis: 28.6% in polycythemia vera (PV), 20.7% in essential thrombocytosis, and 9.5% in myelofibrosis.1 COVID-19 has also been associated with thrombosis, and there are similarities in the pathophysiology which raise concerns about the elevated risk that COVID-19 poses to patients with MPN.2
On the second day of the Texas Virtual MPN Workshop (TMW) 2020: First Annual Workshop and Meeting, Laura Michaelis, Medical College of Wisconsin2 and Brady Stein, Feinberg School of Medicine, Northwestern University,1 each gave a presentation on COVID-19 and MPN. Here, we are pleased to summarize the key points of their talks.
As highlighted by Laura Michaelis, there is little information and limited sources of information regarding general management of MPN in the COVID-19 pandemic. Current knowledge is based on published literature, registries, biological expectations, and expert guidelines.
There are two registries aiming to gather information on COVID-19 in patients with solid tumors/hematological malignancies:
Other studies have demonstrated that having cancer was found to be the highest risk factor for severe events during a COVID-19 infection (OR, 5.3; 95% CI, 1.8–16.2; p = 0.003).2 The fatality rate in cancer patients ranged from 5–28%, compared with 2.3% in patients without cancer.2 A smaller cohort study at two centers in Wuhan, China conducted by Wenjuan He et al,3 investigated 129 hospitalized patients with hematological malignancies and 226 healthcare providers (HCPs). They found that 10% of patients (n = 13) developed COVID-19 compared to 7% (n = 16) of HCPs. Also, patients with hematological malignancies had an increased disease severity and risk of death compared to 11 hospitalized HCPs with COVID-19 (Table 1).
Table 1. The comparison of outcomes of patients with hematological cancer and hospitalized healthcare workers with COVID-192
Outcome |
Patients with hematological cancer (n = 13) |
Healthcare providers (n = 11) |
---|---|---|
Cured |
5 |
8 |
Improved |
0 |
3 |
Dead |
8 |
0 |
Dr Michaelis discussed the unique vulnerabilities of patients with MPN, noting that they may be more likely to get severe disease upon infection, which may be attributed to older age, a higher rate of comorbid conditions, such as pulmonary hypertension, and higher rates of congestive heart failure, peripheral vascular disease, and stroke. Highlighting that COVID-19 is an infection associated with high rates of clotting, this may aggravate complications in MPN leading to an increased risk in patients who would otherwise have been considered low risk.
To understand the risk COVID-19 poses to patients with MPN, and potential treatment strategies, Brady Stein emphasized the high rates of thrombosis in patients with MPN.
A study conducted by Malin Hultcrantz et al.4 with 9,429 patients with MPN and 35,820 matched controls found that patients with MPN are at higher risk of thrombosis at diagnosis (arterial thrombosis, HR 3.0; venous thrombosis, HR 9.7), though the risk still remains 1 year (HR, 2.0 and 4.7, respectively) and 5 years (HR, 1.5 and 3.2, respectively) after diagnosis. Furthermore, 16.2% of patients with MPN present with arterial thrombosis and 6.2% with venous thrombosis. This study confirmed older age and prior thrombosis as risk factors for thrombosis (HR, 2.4 and 2.7, respectively). It also highlighted that a combination of older age (> 60 years old) and prior thrombosis greatly increased the risk of thrombosis (HR, 7.0).
Thrombosis risk classification varies for different subtypes of MPNs (Table 2).
Table 2. Thrombosis risk groups in MPN subtypes1
CV, cardiovascular; ET, essential thrombocytosis; MF, myelofibrosis; PV, polycythemia vera. |
||
Subtype |
Risk groups |
Risk factors |
---|---|---|
PV |
Low risk |
Age ≤ 60 years, no prior thrombosis |
High risk |
Age > 60 years, prior thrombosis |
|
ET |
Very low risk |
Age ≤ 60 years, no thrombosis, JAK2 negative |
Low risk |
Age ≤ 60 years, no thrombosis, JAK2 positive |
|
Intermediate |
Age > 60 years, no thrombosis, JAK2 negative |
|
High risk |
Age > 60 years and JAK2 positive or prior thrombosis |
|
Early MF |
Low risk (0–1 points) |
Age (1 point) CV risk (1 point) Prior thrombosis (2 points) JAK status (2 points) |
Intermediate risk (2 points) |
||
High risk (> 2 points) |
Other variables, such as blood cell quantity, are also important factors in thrombosis risk.
As the effect of mutations in patients with MPN is becoming better understood in terms of thrombosis risk, it becomes increasingly clear that mutations matter.
Different mutations result in varying thrombosis, risk depending on the specific MPN. For example, in essential thrombocytosis, CALR mutations have a 10-year cumulative incidence (CI) of thrombosis of 5%, whereas the MPL mutation conveys the highest risk of thrombosis, with a 10-year CI of 19.5%. In myelofibrosis, CALR mutations are the lowest risk but have a 10-year CI of 13.6%, with the JAK2 V617F mutation being the highest risk at a 10-year CI of 18.3%. In patients with PV, thrombosis risk seems to be influenced only by the JAK2 V617F variant allele frequency.1
In recent studies modelling JAK2 V617F mutations, a pro-thrombotic phenotype has been found to occur due to changes in endothelial expression of P-selectin and β1/β2 integrins, leading to increased neutrophil extracellular traps, which are thought to affect how white blood cells adhere to the endothelium and may increase MPN-associated thrombosis.1
As Dr Stein highlighted, MPN-related thrombosis is very complex with contributions of multiple factors, including CV risk factors, gender, age, thrombosis history, inflammation (CRP/pentraxin 3), leukocytosis, and erythrocytosis.
COVID-19 has a distinct form of coagulopathy which comes with:
Possible contributors to COVID-19 thrombosis include platelet activation, thrombin generation, complement activation, antiphospholipid antibodies, and suppression of fibrinolysis following inflammatory stress. This concept is called ‘thromboinflammation’, suggesting that it is a surge of inflammation which leads to downstream effects causing thrombosis. It is worth noting that this pattern is also seen in MPN.1
Autopsy studies have shown severe endothelial injury, accompanied by intracellular virus particles, and widespread thrombosis with microangiopathy. This suggests that the thrombosis risk associated with COVID-19 may not only be attributed to thromboinflammation but also to endotheliopathy. Whether this is a cause or consequence of multi-organ failure is still unknown.
Surveys among treating physicians have shown that the management of hematological disorders, including MPN, was similar following a diagnosis of COVID-19, with mild modifications.
The current recommendations for treatment of patients with MPN in the era of COVID-19, and how these translate to clinical practice, are summarized from both presentations in Table 3.
Table 3. Summary of current recommendations in patients with MPN and with/without COVID-191,2
DVT, deep vein thrombosis; ET, essential thrombocytosis; HCT, hematocrit; LMWH, low-molecular-weight heparin; MPN, myeloproliferative neoplasms; PE, pulmonary embolism; PV, polycythemia vera; WBC, white blood cell. |
||
|
Recommendations |
In practice |
---|---|---|
Patients without infection
|
No data to support cytoreduction adjustment Consider changes to phlebotomy schedules perhaps to reduce hospital visits No data to support JAK2 inhibition adjustments but given immunosuppressive effects, risk/benefit discussions should be undertaken on whether to initial therapy |
HCT control < 45% in PV Anti-platelet therapy in ET and PV patients with an indication (consider twice daily administration) Cytoreduction: WBC < 10 × 109 per L, platelets < 400 × 109 per L
|
Patients with infection |
Adjust MPN therapy if there are potential drug-drug interactions Consider enrolling patients on COVID-19 trials No data to suggest changing from fedratinib or other agents to ruxolitinib Anticoagulation may need to be adjusted: Patients on oral anticoagulation may need to transition to LMWH, if on LMWH + aspirin, consider bleeding risk, as COVID-19 may provoke severe thrombocytopenia |
Known or suspected COVID-19 patients: Prophylactic dose of LMWH/heparin for critically ill patients Suspect PE in cases of sudden respiratory deterioration with or without other clinical evidence of DVT, especially if there is a sudden increase in d-dimers |
In patients already on anticoagulation: Switch to LMWH If taking aspirin, continue especially those taking it for secondary prevention Addition of LMWH to aspirin – weigh up against possible bleeding risk Careful monitoring of blood counts and coagulation parameters to intercept cytopenias or coagulation abnormalities |
While ruxolitinib has been associated with improved outcomes after severe COVID-19 infection, it is unclear whether JAK inhibition would also convey a protective effect, and there are trials ongoing to assess ruxolitinib (alone and in combination with other immunomodulatory agents) for the treatment of COVID-19 in various settings. Other agents currently under investigation include tofacitinib and baricitinib. It is worth noting that ruxolitinib treatment should not be stopped in patients with MPN and COVID-19 as there may be some benefit in terms of cytokine protection.2
Laura Michaelis described COVID-19 as a disorder of the blood, leading to thrombotic events which may be amplified in patients with MPN. Furthermore, studies have shown that there is a higher risk for more severe COVID-19 disease and death in patients with MPN. Although there is insufficient data for evidence-based management of COVID-19 in patients with MPN, treatment guidelines have been developed mostly based on expert consensus. It is important to remember that patients are concerned regarding their infection risk and the risk of severe illness. Online sources, such as the ASH COVID-19 resources, provide information for treating clinicians to support the decision-making process. Current studies are ongoing to address the role of JAK inhibition for the treatment of COVID-19. Healthcare professionals are encouraged to register patients with COVID-19 and MPN in online databases such as the ASH COVID-19 Registry or CCC-19 in order to support the clinical learning process.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox